Patent protection rules that curb competition for medicines in markets outside the European Union should be changed, the European Commission has proposed, reported Reuters.
The Commission says it wants to introduce an “export manufacturing waiver” to protections for the pharmaceuticals sector known as supplementary protection certificates (SPC).
An SPC is an EU-wide intellectual property right that extends the protection of a patented medicine by up to five years. SPCs effectively compensate patent holders for time lost in getting regulatory approval for medicines.
According to the Irish Times, under the current regulation, European-based manufacturers are prevented from producing medicines even for regions outside the EU during the period of an SPC, despite the fact that those markets may not be subject to a supplementary protection certificate or where it might already have expired.
Generics and biosimilar manufacturers, which produce “me too” versions of drugs that have come off patent, have been pressing for a number of years for a waiver covering European manufacture for such markets outside the EU.
The European Commission last year launched a public consultation on SPCs. The announcement Monday, May 28, is the outcome of that process.
Full Content: Reuters, Irish Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI